Abstracts 133 SIONS: Our model provides evidence than an effective AIDS intervention in a high-risk population of out-oftreatment substance abusers can avert significant numbers of new HIV infections, which may offset initial costs.
OBJECTIVE: Studies evaluating predictors of heathrelated quality-of-life (HRQOL) in patients infected with HIV have primarily been limited to clinical, sociodemographic, and psychological factors. Little is known about the relationship between HRQOL and behaviors such as medication adherence or complementary and alternative medicine (CAM) use. The purpose of this study was to determine the clinical, sociodemographic, and behavioral predictors of HRQOL. METHODS: A sample of 242 HIV-infected patients was recruited. Data were collected using a self-administered instrument containing the Medical Outcomes Study (MOS)-HIV Health Survey and items relating to CAM use, medication adherence, and sociodemographic characteristics. Clinical information was abstracted from medical records. Independent associations of the Mental (MHS) and Physical Health Summary (PHS) scores with CD4 cell counts, HIV-1 viral loads, CAM use, self-reported medication adherence, antiretroviral use, and sociodemographic characteristics were assessed. Linear regression models were created for each score. Variables independently associated (p Ͻ 0.05) with a score were entered into that model. RESULTS: The mean MHS and PHS scores were 46.6 and 42.8, respectively. Education, income, CAM use, and self-reported adherence to HIV medication regimens were independently associated (p Ͻ 0.03) with MHS scores. PHS scores were independently associated (p Ͻ 0.003) with age, income, HIV-1 viral load, CD4 count, and CAM use. In the multivariate analyses, income and self-reported adherence were found to be significant (p Ͻ 0.005) predictors of the MHS scores (Adj. R2 ϭ 0.197); age, income, CD4 counts, and CAM use were found to be significant (p Ͻ 0.03) predictors of PHS scores (Adj. R2 ϭ 0.182). CON-CLUSIONS: Our research suggests that, along with clinical and sociodemographic characteristics, self-reported behaviors are important predictors of HRQOL among HIV-infected patients.
PID15

MANAGING AIDS IN THE ERA OF ANTIRETROVIRAL THERAPY: CHANGES IN THE RATE AND COST OF HOSPITALIZATIONS
O'Brien JA, Pierce D, Patrick AR, Caro JJ Caro Research Institute, Concord, MA, USA BACKGROUND: Clinical trials have shown that highly active antiretroviral therapy (HAART) alters the natural progression of HIV. This study was undertaken to determine if, apart from the beneficial clinical impact, there has been a change in the cost of AIDS-related care. METHODS: Data from the Massachusetts (MA) Department of Public Health and hospital discharge databases for 1995-1998 were used to examine changes in hospital admission and discharge patterns, and hospital costs for adults with AIDS across the four years. Analyses involved log transformation to address highly skewed distributions, ANOVA to compare continuous variables and Chi-Square to compare the proportions. Hospital costs in-clude all accommodations and ancillaries. Cost estimates, adjusted for medical inflation and cost-to-charge ratios, are reported in 1998 US$. RESULTS: From 1995 to 1998, the rate of hospital admissions for MA residents with AIDS declined substantially. In 1995, 86% of the 3,162 AIDS patients were admitted at least once during the year compared to 31% of the 5,636 patients in 1998. The mean number of annual admissions per patient dropped from 2 to 1.76 and the inpatient case fatality rate fell from 6.7% to 4.6%. The mean LOS per AIDS admission fell by 1.3 days; a greater decline than the 0.4 day average observed in MA over the same period. The mean hospital stay cost decreased from $8,070 to $7,538. These changes accounted for a $2,900 drop in the mean annual hospitalization cost per AIDS patient during that time. Discharge to sub-acute inpatient and home health services fell by 8.6% in this period. All changes reported are statistically significant (p Ͻ 0.05).
CONCLUSIONS:
The change in LOS is not the result of post-discharge resource use shifting. The decrease in resource use and costs observed after the introduction of HAART are consistent with an economically beneficial impact of these agents. Although information exists in the form of projected costs, limited data are available on the overall cost of illness resulting from varicella-zoster virus (VZV) infection. VZV is usually a benign childhood illness, but reactivation of latent VZV can lead to serious complications. OBJECTIVE: To assess via medical claims the costs associated with VZV infection and its resultant complications from the payers' perspective. METHODS: We conducted a retrospective database analysis of 73,869 managed care members continuously enrolled throughout calendar year 1999. Records of members with a diagnosis code of either primary varicella (ICD9-052) or herpes zoster (ICD-053) were selected. Data was extracted and cost information was tallied for all medical claims including inpatient hospitalizations, primary care visits, specialist visits, emergency department visits, and specialty procedures. Cost data are reported in 1999 US dollars. RESULTS: In 1999, a total of 119 patients were diagnosed with varicella (52%) and herpes zoster (48%). The mean cost to the payer was $496.77/patient. The average amount paid out for members with varicella was $181.87. The average cost per member with herpes zoster was $786.27. Sixtytwo (52%) VZV afflicted members were diagnosed with varicella while 57 were diagnosed with herpes zoster. The amount paid for members over age 19 (n ϭ 56) was $640.30/patient. Of these patients, 14% were classified with varicella infection, whereas 86% were classified as having zoster. For members aged Ͻ19 (n ϭ 63), the mean amount paid was $369.18/patient. In this group, 78% were diagnosed with varicella infection, whereas 22% were diagnosed with zoster. CONCLUSION: The above costs document for the first time the true cost of VZV infection from the payers' perspective. Further efforts to expand vaccination programs should take these costs into consideration.
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COST BURDEN OF VARICELLA-ZOSTER VIRUS INFECTION IN A MANAGED CARE SETTING
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ECONOMIC EVALUATION OF OSELTAMIVIR FOR INFLUENZA PATIENTS IN JAPAN
Kobayashi M Crecon Research and Consulting Inc, Tokyo, Japan OBJECTIVES: The aim of this analysis is to estimate the economic impacts of oseltamivir treatment for influenza in Japan. METHODS: A decision tree with endpoints of occurrences of pneumonia was constructed to compare two treatment strategies, oseltamivir treatment and conventional treatment, for otherwise healthy adult (over 16) patients with influenza like illness in Japan. Drug consumption data (e.g., acetaminophen, antibiotics, and palliative drugs for influenza like illness related symptoms) were collected prospectively as well as work absenteeism data as part of the Japanese placebo-controlled doubleblind multicenter study by oseltamivir that included 316 patients. Parameters used in the decision tree were mainly derived from this study and combined with published data. Sensitivity analyses were also performed to examine the robustness of the results. RESULTS: Expected total medical cost per patient was 14,100 yen and 14,412 yen for oseltamivir treatment and conventional treatment, respectively. Expected cost including production loss was 56,654 yen and 63,485 yen, for oseltamivir treatment and conventional treatment, respectively. Based on the results of basic analyses, the savings that could be expected in Japanese nationwide health care costs with widespread use of oseltamivir ranged from 1.1 billion yen to 3.4 billion yen. CONCLUSION: This study suggested that oseltamivir treatment for patients with flu-like symptoms can be attractive from the societal perspective in Japan.
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METHICILLIN-RESISTANT STAPHYLOCOCCUS SPECIES TREATMENT PATTERNS IN CANADA Becker D, Rosner AJ Innovus Research Inc, Burlington, ON, Canada
Antibiotic resistance is of growing importance to the Canadian health care system due to the morbidity, mortality, and financial costs of certain pathogens for which there are limited therapeutic options. Among the resistant organisms, the incidence of methicillin-resistant Staphylococcus species (MRSS) is rising and is posing an increasing burden to health care systems. OBJECTIVE: To characterize MRSS treatment patterns in patients with
